Integrated mRNA and microRNA transcriptome sequencing characterizes sequence variants and mRNA–microRNA regulatory network in nasopharyngeal carcinoma model systems  by Szeto, Carol Ying-Ying et al.
FEBS Open Bio 4 (2014) 128–140 
I
v
m
C
G
a
b
c
d
e
a
A
R
R
A
K
N
R
T
N
H
T
 

m
c
a
R
n
G
t
n
M
t
m
f
2
hj o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / f e b s o p e n b i o 
ntegrated mRNA and microRNA transcriptome sequencing characterizes sequence 
ariants and mRNA–microRNA regulatory network in nasopharyngeal carcinoma 
odel systems  
arol Ying-Ying Szeto a , b , Chi Ho Lin c , Siu Chung Choi c , Timothy T.C. Yip a , e , Roger Kai-Cheong Ngan a , e , 
eorge Sai-Wah Tsao a , d , Maria Li Lung a , b , * 
 Center for Nasopharyngeal Cancer Research, The University of Hong Kong, PR China 
 Department of Clinical Oncology, The University of Hong Kong, PR China 
 Centre for Genomic Sciences, The University of Hong Kong, PR China 
 Department of Anatomy, The University of Hong Kong, PR China 
 Department of Clinical Oncology, Queen Elizabeth Hospital, PR China 
 r t i c l e i n f o 
rticle history: 
eceived 10 September 2013 
eceived in revised form 9 January 2014 
ccepted 9 January 2014 
eywords: 
asopharyngeal carcinoma 
NA sequencing 
ranscriptome analysis 
asopharyngeal cell lines / xenograft (NP460, 
K1, C666, X666) 
P53 
a b s t r a c t 
Nasopharyngeal carcinoma (NPC) is a prevalent malignancy in Southeast Asia among the Chinese pop- 
ulation. Aberrant regulation of transcripts has been implicated in many types of cancers including NPC. 
Herein, we characterized mRNA and miRNA transcriptomes by RNA sequencing (RNASeq) of NPC model 
systems. Matched total mRNA and small RNA of undifferentiated Epstein–Barr virus (EBV)-positive 
NPC xenograft X666 and its derived cell line C666, well-differentiated NPC cell line HK1, and the im- 
mortalized nasopharyngeal epithelial cell line NP460 were sequenced by Solexa technology. We found 
2812 genes and 149 miRNAs (human and EBV) to be differentially expressed in NP460, HK1, C666 and 
X666 with RNASeq; 533 miRNA–mRNA target pairs were inversely regulated in the three NPC cell lines 
compared to NP460. Integrated mRNA / miRNA expression proﬁling and pathway analysis show extra- 
cellular matrix organization, Beta-1 integrin cell surface interactions, and the PI3K / AKT, EGFR, ErbB, 
and Wnt pathways were potentially deregulated in NPC. Real-time quantitative PCR was performed 
on selected mRNA / miRNAs in order to validate their expression. Transcript sequence variants such as 
short insertions and deletions (INDEL), single nucleotide variant (SNV), and isomiRs were characterized 
in the NPC model systems. A novel TP53 transcript variant was identiﬁed in NP460, HK1, and C666. 
Detection of three previously reported novel EBV-encoded BART miRNAs and their isomiRs were also 
observed. Meta-analysis of a model system to a clinical system aids the choice of different cell lines in
NPC studies. This comprehensive characterization of mRNA and miRNA transcriptomes in NPC cell lines 
and the xenograft provides insights on miRNA regulation of mRNA and valuable resources on transcript 
variation and regulation in NPC, which are potentially useful for mechanistic and preclinical studies. 
C © 2014 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical 
Societies. All rights reserved.  This is an open-access article distributed under the terms of the Creative Com- 
ons Attribution-NonCommercial-No Derivative Works License, which permits non- 
ommercial use, distribution, and reproduction in any medium, provided the original 
uthor and source are credited. 
Abbreviations: NPC, nasopharyngeal carcinoma; EBV, Epstein–Barr virus; RNASeq, 
NA sequencing; miRNA, microRNA; NGS, next-generation sequencing; SNP, single 
ucleotide polymorphism; INDEL, insertion and deletion; UTR, untranslated region; 
O, gene ontology; ECM, extracellular matrix; EGFR, epidermal growth factor recep- 
or; PI3K, phosphoinositide 3-kinase; EGR1, early growth response 1; GNG11, guanine 
ucleotide binding protein (G protein), Gamma 11; DKK1, Dickkopf-Like protein 1; 
ET, met proto-oncogene; CIITA, class II, major histocompatibility complex, transac- 
ivator; IL18, interleukin 18; TNFRSF9, tumour necrosis factor receptor superfamily, 
ember 9; MMP19, matrix metallopeptidase 19; FBLN2, ﬁbulin 2; LTBP2, latent trans- 
orming growth factor beta binding protein 2; PTEN, phosphatase and tensin homolog; 
211-5463/ $ 36.00 c © 2014 The Authors. Published by Elsevier B.V. on behalf of Federation o
ttp://dx.doi.org/10.1016/j.fob.2014.01.004 1. Introduction 
Nasopharyngeal carcinoma (NPC) is a prevalent malignant disease 
in Southeast Asia among the Chinese population. According to the 
Hong Kong Cancer registry statistics, a high incidence rate of 15.1 / LMP1, Epstein–Barr virus latent membrane protein 1; AIP, aryl hydrocarbon recep- 
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 100,000 in men has been observed in Hong Kong, while the incidence
rate in Western countries is much lower ( < 1 / 100,000) [ 1 ]. NPC is
classiﬁed by WHO into three types: type I keratinizing squamous car-
cinoma, type IIA non-keratinizing differentiated carcinoma, and type
IIB non-keratinizing undifferentiated carcinoma [ 2 ]. The majority of
NPC cases in Western countries are type I, such as in the United States,
where it accounts for 75% of all NPC cases [ 3 ]. Most NPC cases from
the Southeast Asia region are type II [ 4 ]. Type II NPC is constantly as-
sociated with Epstein–Barr virus (EBV) infection, but the association
between type I NPC with EBV is still controversial [ 5 ]. 
In the past 30 years, several NPC cell lines and xenograft mod-
els have been established for the in vitro study of NPC. Examples
such as the C666, CNE-1, CNE-2, HK1, HNE-1, and HONE-1 NPC cell
lines were established from biopsies [ 6 –9 ], while a series of nonma-
lignant nasopharyngeal epithelial cell lines were also established by
immortalization from primary cultures [ 10 ]. Xenograft models such
as X(eno)-666, X(eno)-2117, X(eno)-1915, C15, and C17 were estab-
lished in a rodent xenograft system [ 11 –14 ]. They are valuable models
for research in NPC. 
Aberrant transcript expression includes changes in expression lev-
els, isoforms, and polymorphisms, which are commonly observed in
cancer; these aberrations could alter biological pathways and disease
phenotypes. Next-generation sequencing (NGS) of RNA (RNASeq) has
become a popular tool for studying the comprehensive transcriptome
in recent years. Despite the improving sensitivity and dynamic range
of the gene expression array, RNASeq still plays a vital role in provid-
ing sequence information of the transcript that greatly enhances our
knowledge of the transcriptome in cancer [ 15 ]. The microRNAs (miR-
NAs) are a class of small non-coding RNAs that regulate mRNA through
sequence-speciﬁc binding to the UTR [ 16 ]. Studies on miRNA dysreg-
ulation in cancers have risen rapidly in recent years, including those in
NPC. miRNAs such as hsa-mir-141, hsa-mir-138, hsa-mir-200a, and
hsa-mir-26a are altered in NPC and regulate cell proliferation, cell
cycle, extracellular matrix organization, migration, and invasion [ 17 –
20 ]. In addition to human miRNAs, NPC is also associated with EBV
infection. The host-virus interaction has been thoroughly studied in
B lymphocytes and it has been found that host transcriptional regula-
tors play a role in EBV gene regulation, while EBV-encoded microRNAs
induce cell transformation [ 21 , 22 ]. Regulation of both human and EBV
gene expression by EBV-encoded miRNA has been observed in NPC.
For example, expression of ebv-mir-BART-22 modulates expression of
the EBV-encoded LMP2A protein, which is related to the host immune
response [ 23 ]. The expression of ebv-mir-BART3 targets the DICE1 tu-
mor suppressor that stimulates cell proliferation [ 24 ]. Several studies
on expression proﬁling of miRNA from clinical biopsy samples have
been reported on both EBV and human miRNAs [ 25 –27 ]. However,
studies on concurrent transcriptome characterization of both mRNA
and miRNA are still lacking. 
This study is to characterize the mRNA and miRNA transcriptome
in NPC models, which provides a global view of transcript regulation
in an in vitro system ( Fig. 1 A). NP460 is a well-established immor-
talized nasal epithelium cell line usually used as a control for mech-
anistic studies [ 10 ]. HK1 is one of the few well-differentiated NPC
cell lines [ 8 ]. Xeno-666 (X666) and the subsequent cell line C666 are
the only undifferentiated cell line and xenograft pairs that harbor
EBV infection for EBV studies in NPC [ 6 ]. Biological pathways such
as extracellular matrix organization, integrin signaling, angiogenesis,
and hypoxia are commonly enriched in NPC cell lines. The miRNA-
regulated pathways such as EGFR signaling are enriched in both HK1
and C666 / X666. The miRNA-regulated nuclear beta catenin signaling
is exclusively enriched in HK1, while the Wnt signaling pathway is en-
riched solely in C666 / X666, respectively. Real-time quantitative PCR
was performed on the selected miRNA-regulated biological networks
like EGFR signaling and cytokine and interferon signaling in NPC and
NP cell lines. 
We also explored sequence variants in transcripts such as SNVsand short INDELs in the NPC model system and integrated these tran-
scriptomes to publicly available microarray data from clinical speci-
mens. A novel TP53 variant in a transcript has been discovered from
the SNV. The meta-analysis of these model systems to clinical speci-
mens aids the choice of different cell lines in various NPC studies. 
IsomiRs are heterogeneous variants of miRNAs in length and se-
quence. Recent studies suggested that isomiRs may interact with
mRNA, affecting target selection, miRNA stability, and translational
machinery [ 28 ]. Here we report a comprehensive collection of human
and EBV-encoded isomiRs from the NPC model system and identiﬁed
a number of substantially expressed EBV-encoded isomiRs, which
may be considered as reference miRNAs in NPC. We discovered the
existence of three previously reported novel EBV-miRNAs in C666 and
X666 [ 26 ], which may play mechanistic roles in NPC. This report not
only provides a fundamental picture of global gene and miRNA–mRNA
regulation in NPC, but also provides potentially useful candidates for
future mechanistic and preclinical studies. 
2. Material and methods 
2.1. Sample preparation, DNA and RNA extraction 
Early passages of NPC cell lines, HK1, C666, and NP460, and the
X666 xenograft were utilized for this study. DNAs were extracted from
cell lines and the xenograft using the QIAGEN DNA extraction kit ac-
cording to manufacturer instructions. DNA genotyping of cell lines
authenticated their origins. Real-time quantitative EBV DNA PCR was
performed on cell lines, as previously described [ 29 ]. EBV DNA was
only detected in C666 and no EBV DNA was detected in HK1 and
NP460 cell lines (data not shown). All the cell lines were re-grown in
standard conditions [ 6 , 8 , 10 ]. Cells were collected from three subse-
quent culture passages upon reaching ∼80% conﬂuence, as described.
Total RNA was extracted with TRIZOL reagent (Invitrogen, NY, USA)
according to standard procedures. Integrity of RNA was checked by
Agilent 2100 bioanalyzer using the RNA 6000 Nano total RNA assay,
with RIN value > 8.9. RNA from the earliest passage of each cell line
was selected for Solexa sequencing. 
2.2. Solexa sequencing, read processing and sequence alignment 
The sequencing library was prepared with the standard Illumina
protocol. Brieﬂy, total RNA was poly-A-selected to deplete the riboso-
mal RNA fraction. The cDNA was synthesized using random hexamers,
end-repaired and ligated with appropriate adaptors for sequencing.
The library then underwent size selection and PCR ampliﬁcation, fol-
lowed by PAGE puriﬁcation before sequencing. Stranded small RNA
libraries were prepared by ligating different 3 ′ and 5 ′ adaptors se-
quentially to the total RNA followed by reverse transcription and PCR
ampliﬁcation. Small RNAs with insert sizes of 20–70 bp were PAGE-
puriﬁed for sequencing. Both mRNA and small RNA libraries were
sequenced on the Illumina Solexa GAIIx sequencer with 58 bp single-
end reads, according to the standard manufacturer’s protocol. Raw
RNASeq reads were ﬁltered for adapters and ribosomal RNA, followed
by alignment to the human genome (hg19) and mouse genome (mm9)
using the Tophat [ 30 , 31 ] v2.0.3.1. Reads mapped to multiple locations
were discarded using the −G option of Tophat. UCSC gene models
were used for analysis with both software and downloaded from the
Tophat website ( http: // tophat.cbcb.umd.edu / igenomes.html ). CLC
genomics workbench v5.5 (CLC bio, Denmark) was used for small RNA
analysis. Adapters were trimmed under default parameter setting to
retain only reads with lengths ≥15 bp. These reads were then mapped
and annotated against the miRBase [ 32 –35 ] (release 19). Read counts
of the annotated miRNA were exported from CLC genomics work-
bench and RPM (Reads per million base pairs) were calculated us-
ing customs scripts. Non-annotated reads were further mapped to
Ribosomal RNA (rRNA), Transfer RNA (tRNA), Small nucleolar RNA
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Fig. 1. An overview of the samples used in this study and data analysis workﬂow. (A) Cell lines sequenced in this study. (B) Bioinformatics analysis workﬂow. 
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 (snoRNA), Messenger RNA (mRNA), Small nuclear RNA (snRNA), and
genomic repeats. IsomiRs were analyzed based on CLC results using
custom scripts based on mature reference sequences from miRBase
and novel EBV-miRNA from Chen et al. [ 26 ]. 
2.3. miRNA target prediction 
The miRNA target prediction was done by scripts from Targetscan
[ 36 ], PITA [ 37 ], and miRanda [ 38 ]. Human UTRs were downloaded
from the Targetscan website sourced from UCSC genome informat-
ics; mature miRNAs were downloaded from the miRBase (release
19). Human UTRs, which encode genes that were signiﬁcantly ex-
pressed ( p < 0.05) in at least two samples, were further selected
for the algorithms to predict against those human and EBV miRNAs,
which are signiﬁcantly expressed in at least two samples. High ef-
ﬁcacy targets were selected by the following cutoffs: (i) Targetscan:
sum of the context score < −0.2; (ii) PITA: sites with G ≤ −10 kcal /
mol; (iii) miRanda: score ≥ 155, energy ≤ −20 kcal / mol. Predicted
miRNA–UTR pairs were further selected according to the integrating
mRNA and miRNA transcript expression data. A two-fold cutoff was
set for deﬁning up / down regulation and target pairs with inverse ex-
pression. For miRNA-binding UTR analysis, 25 base pairs upstream /
downstream of the UTR sequence from the SNP / INDEL were down-
loaded from UCSC and predicted the miRNA binding site against all
human and EBV miRNAs from the miRBase by the three prediction al-
gorithms (Targetscan, PITA, and miRanda). For the predicted binding
site by at least 2 of the 3 aforementioned algorithms, we replaced the
reference sequence with the variant and carried out the prediction
again with all the reference and variant sequences. 
2.4. Biological network and function enrichment analysis 
Network analysis, biological pathway, and gene ontology (GO)
term enrichment were done using the Reactome FI [ 39 ] plug-in of
Cytoscape [ 40 ]. Gene lists from each expression set with signiﬁcant
expression ( p < 0.05) in the respective comparisons were loaded as
input and the biological network was constructed by the gene set
analysis of Reactome FI. Biological pathway and Gene Ontology Bio-
logical Function terms enrichment were performed using input genes
from the biological network. Pathway and GO terms with adjusted
p < 0.05 were considered to be enriched in the biological network. 
miRNA–mRNA target expression pairs, which have signiﬁcant ex-
pression in respective comparison from the previous section, were
chosen. Then the expression networks of those selected pairs were
constructed by deﬁning the target pair interaction between miRNA
and its target gene. These expression networks were further merged
with the respective biological network, which was constructed from
the Reactome FI containing all mRNA genes coming from the same
expression set. Biological network of the miRNA–mRNA target plus
the ﬁrst-degree neighbor of the mRNA target were selected as the
miRNA regulatory network. Pathway and function term enrichment
was further performed as stated above. 
2.5. SNP / INDEL detection and characterization 
Variant calling was done using VarScan [ 41 ] v2.2.11 with ﬁlter-
ing criteria of at least 10 × coverage, variation frequency of more
than 10%, and base quality of more than 15. Variants that passed the
ﬁltering criteria were annotated using ANNOVAR with COSMIC64 an-
notation [ 42 ]. DNA sequence logos were generated using WebLogo
generator [ 43 ]. 2.6. Statistical analysis 
The following statistical analyses were performed on R (version
2.15.1) with respective packages and a p -value of < 0.05 was con-
sidered as signiﬁcant. Expression analysis of mRNA and miRNA was
done using the DESeq package [ 44 ], which uses the read counts
as input. Meta-analysis of mRNA expression and microarray ex-
pression data downloaded from Gene Expression Omnibus ( http: //
www.ncbi.nlm.nih.gov / geo / ) were performed by the MetaDE R pack-
age [ 45 ]. Fisher exact test was used and a p -value of < 0.05 was set as
the cutoff. 
2.7. Reverse transcription (RT) and real-time quantitative PCR (QPCR) 
To quantitate mRNA expression, the total RNA from each sam-
ple was reverse transcribed into cDNA using MMLV (USB, Cleveland,
OH). Speciﬁc primers were either from the literature or designed
using Primer 3 software [ 46 ]; the sequences and references of the
primers are listed in Supplement 1 . Real-time QPCR was performed
on Light-Cycler Roche 480 (Roche Molecular Systems). PCR was per-
formed in a total volume of 10 μl containing 50 ng of total cDNA,
1 × FastStart Universal SYBR Green master mix (Roche) and a ﬁnal
primer concentration as stated in Supplement 1 . Detection of mature
miRNA expression was performed by TaqMan miRNA assay (Applied
Biosystems, Foster City, CA, USA), normalized using small nucleolar
RNA RNU44 as a control. The relative expression level was analyzed
by the Ct method [ 47 ] or using the Pfafﬂ model [ 48 ]. One-way
ANOVA was followed by Tukey post hoc analysis, where a p < 0.05
was considered statistically signiﬁcant. 
3. Results 
3.1. Overview of transcriptome sequencing results of NPC cell lines 
To reveal the transcriptome of NPC model systems, we sequenced
the mRNA and small RNA from the same total RNA samples from the
early passages of model NPC cell lines and xenograft using Solexa
GAIIx. From the four mRNA libraries, an average of 30,277,744 single-
end 58 bp reads were generated ( Supplement 2 ); four small RNA
libraries were also sequenced and 25,613,996 single-end 58 bp reads
were generated on average. After performing the quality ﬁlter, mRNA
sequence reads were aligned to the human (hg19) and mouse (mm9)
genomes, while small RNA sequence reads were aligned to miRBase
(see Section 2 ). A total of 2812 mRNAs and 149 miRNAs (human
and EBV) were differentially expressed ( p < 0.05) with any combi-
nation of the four samples sequenced ( Fig. 1 B). Detailed sequencing
data has been uploaded to the GEO database with accession number
GSE54174. 
We then analyzed the differences and similarity of the
differentially-expressed transcripts that contribute to carcinogene-
sis. A Venn diagram of differentially-expressed mRNAs and miRNAs
against the immortalized nasopharyngeal epithelial cell line NP460
shows that 368 protein-coding genes and 12 miRNAs were signiﬁ-
cantly expressed in common among the NPC cell lines ( Fig. 2 A). The
749 mRNAs and 37 miRNAs show signiﬁcant expression changes only
in HK1. On the other hand, 963 mRNAs and 62 miRNAs are differ-
entially expressed in C666, but not HK1 ( Fig. 2 A). For the cell line
samples, less than 0.03% of the transcripts were aligned to the mouse
genome, while 5% of the transcripts aligned to mouse for the X666
xenograft. Considering the possible contamination of mouse homolog
transcript by host cells from the xenograft, transcripts expressed sig-
niﬁcantly in the X666 xenograft were not included in the analysis
( Supplement 2 ). 
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Fig. 2. Differentially expressed genes / miRNAs in HK1 and C666 compared to NP460 
and relevant biological pathways / functions in transcriptome data. (A) Venn diagram 
showing the number of protein coding gene / microRNA differentially expressed in HK1 
and C666 compared to NP460. (B) List of Biological pathways and Gene Oncology Bio- 
logical Functions from Reactome FI analysis. Terms begin with circle: enriched in mRNA 
only; terms begin with diamond: enriched in mRNA and miRNA; terms begin with rect- 
angle: enriched in miRNA only; (P): term from Reactome pathway enrichment; (G): 
term from Gene Oncology Biological Process. 
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d.2. miRNA target prediction and integration of mRNA and miRNA 
xpression proﬁles 
To our knowledge, the resources available for the target predic- 
ion for EBV-encoded miRNAs to human 3 ′ -UTR are limited; many 
f the public target prediction databases do not have the miRBase 
release 19) for human miRNAs. Thus, we ran our in-house miRNA 
arget prediction using scripts from Targetscan [ 36 ], PITA [ 37 ], and 
iRanda [ 38 ]. We ran the three prediction algorithms using the 149 
iRNAs and UTR of the 2812 mRNAs, which are expressed signif- 
cantly, as input. This resulted in 7951 miRNA–mRNA target pairs, 
hich were predicted from at least two out of three algorithms with 
igh efﬁcacy. We further integrated transcript expression data into 
he predicted miRNA–UTR pairs to validate target pairs. We set the 
utoff at two-fold for deﬁning up / down regulation and focused on 
he pairs which are inversely expressed in terms of transcript expres- 
ion. A total of 6423 target pairs were found inversely expressed in 
t least one combination of the expression comparisons. Of the 6423 
arget pairs, 4898 were inversely expressed in at least one NPC model 
ystem (HK1, C666, X666) against NP460, and 533 pairs are inversely 
egulated in all three NPC model systems against NP460 ( Supplement 
 ). 
.3. Molecular pathway and functional enrichment from biological 
etwork analysis 
Network analysis, biological pathway, and gene ontology (GO) en- 
ichment were done for both the signiﬁcantly expressed mRNA gene 
ist and integrated panels of miRNA–mRNA regulation in common 
nd uniquely expressed group of HK1 and C666 against NP460. In or- 
er to enrich the biological function arising from miRNA target pairs, integrated panels of miRNA regulation were generated by selecting 
the direct target of the miRNAs from the results of target prediction 
and the ﬁrst neighbor of the genes that were signiﬁcantly expressed 
from the same group from the mRNA network. Biological network 
analyses of these gene sets were done using the cytoscape plug-in of 
Reactome FI [ 39 ] and a summary of the signiﬁcantly enriched terms 
( p < 0.05) in Reactome pathway and GO Biological Function is listed 
in Supplement 4 . Fig. 2 B shows the important pathway / GO terms 
enriched solely and coherently in NPC cell lines. 
Biological pathways related to extracellular matrix (ECM) orga- 
nization are explicitly enriched in the genes that are signiﬁcantly 
expressed in both HK1 and C666 ( Fig. 2 B). Most of the commonly 
expressed genes from this pathway are down-regulated; two-thirds 
of the genes unique in HK1 are also decreased in expression and 
40% of the unique genes in C666 are up-regulated ( Supplement 4 , 
Supplemental Fig. 1 ). Other ECM-related GO terms / pathways such 
as cell adhesion, beta-1 integrin cell surface interactions, and ECM- 
receptor interactions are also enriched in both HK1 and C666, impli- 
cating the importance of the extracellular matrix in NPC. EGFR and 
PI3K / AKT signaling are enriched only in the miRNA-regulated biolog- 
ical network in the two NPC cell lines ( Supplement 4 ). 
A total of 100 genes enriched in the GO term DNA-dependent 
transcription are signiﬁcantly down-regulated in the HK1 only group 
( Supplement 4 ). The 73 genes from the ZNF family were down- 
regulated, of which 63 genes were located on chromosome 19 
( Supplement 2 ). Several HK1 unique pathways are enriched in both 
mRNA and miRNA regulated biological networks. Pathways such as 
Regulation of retinoblastoma protein and nuclear beta catenin sig- 
naling were enriched in HK1 unique biological network regulated by 
hsa-mir-31–5p and hsa-mir-34b-5p ( Supplemental Fig. 1 ). 
Interferon and VEGF signaling pathways are enriched in the unique 
C666 / X666 mRNA set. This involves up-regulation of MHC class II 
HLA genes (- DRA, -DQA1, -DRB1, -DMA and -DOA ). Interferon signal- 
ing pathway that regulates the expression of this class of proteins is 
also up-regulated solely in C666 / X666. Several biological networks 
enriched in C666 / X666 are also regulated by EBV-encoded miRNA 
( Supplemental Fig. 1 ). Pathways such as Erb and Wnt signaling and 
cytokine-cytokine receptor interactions are enriched. 
Fig. 3 A shows miRNA regulated biological network enriched in 
EGFR, ErbB and Wnt signaling pathways. Expression trend of ﬁve 
protein-encoding genes ( EGFR, EGR1, GNG11, DKK1, and MET ) and 
ﬁve miRNAs (hsa-mir-141–5p, hsa-mir-200c-3p, EBV-mir-BART2–5p, 
EBV-mir-BART14–3p, EBV-mir-BART17–5p) from three subsequent 
passages were validated by real-time QPCR ( Fig. 3 B). EGFR, EGR1, and 
MET are direct targets of EBV-mir-BART14–3p, EBV-mir-BART17–5p, 
and EBV-mir-BART2–5p from our prediction algorithms validated by 
NGS expression, respectively. Three members ( CIITA, IL18, and TN- 
FRSF9) are in the immune-related biological network enriched in cy- 
tokine and interferon signaling ( Fig. 4 A). Their expression from sub- 
sequent passages was also validated by real-time QPCR ( Fig. 4 B). 
3.4. Sequence variants in NPC transcriptome 
Sequence variants analysis detecting SNP and short INDELS was 
carried out using VarScan [ 41 ]. The 17,389 SNP / INDELS were de- 
tected from NP460, HK1, and C666 and the results are summarized in 
Fig. 5 A and Supplement 5 . Sequence variants, which are not solely 
from X666, are also listed in Supplement 5 , while variants solely 
from X666 were removed due to possible contamination of mouse 
sequences. A total of 62% (10,929 / 17,389) of variants are from non- 
protein coding regions, while around 37% (6460 / 17,389) are from 
the exonic regions of the genome ( Fig. 5 A). Of the exonic variants, 
around one-third (2743 / 6460) are non-synonymous or frameshift or 
stopgain / loss, which affect the protein products of the gene. More- 
over, 98 out of 2743 protein-affected variants are genes from the 
catalogue of somatic mutations in the cancer (COSMIC) panel [ 49 ]. Of 
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Fig. 3. microRNA regulated biological network enriched in EGFR, ErbB and Wnt signaling pathways. (A) Network diagram showing Reactome biological network. The intensity of the 
node color indicates the degree of up-(red) or down (green)-regulation with respect to NP460. Round node: protein coding gene; diamond node: human encoded miRNA; triangle 
node: EBV encoded miRNA; orange circle: QPCR-validated genes from three subsequent passages. (B) NGS expression and QPCR expression on QPCR-validated genes. (i) EGFR: 
epidermal growth factor receptor; (ii) EGR1: early growth response protein 1; (iii) GNG11: guanine nucleotide binding protein (G Protein), Gamma 11; (iv) DKK1: Dickkopf-Like 
protein 1; (v) MET: Met Proto-Oncogene; (vi) hsa-miR-141-5p; (vii) has-miR-200c-3p; (viii) EBV-mir-BART2-5p; (ix) EBV-mir-BART14-3p; (x) EBV-mir-BART-17-5p. Error bar on 
QPCR plot: SD from three subsequent passages. * p < 0.05; ** p < 0.01. p Value was estimated by DeSeq package in transcriptome data and by one-way ANOVA followed by Tukey 
post hoc analysis in QPCR, respectively. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.) 
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Fig. 4. Biological network enriched in cytokine and interferon signaling. (A) Network diagram showing Reactome biological network relevant to the genes differentially expressed 
and regulated by miRNA in C666 / X666. The intensity of the node color indicates the degree of up-(red) or down (green)-regulation with respect to NP460. Round node: protein 
coding gene; diamond node: human encoded miRNA; triangle node: EBV encoded miRNA; orange circle: QPCR-validated genes from three subsequent passages. (B) NGS expression 
and QPCR expression on QPCR-validated genes. (i) CIITA: MHC class II transactivator type III; ii) IL18: interleukin 18; iii) TNFRSF9: tumor necrosis factor receptor superfamily, 
member 9. Error bar on QPCR plot: SD from three subsequent passages. * p < 0.05; ** p < 0.01. p Value was estimated by DeSeq package in transcriptome data and by one-way 
ANOVA followed by Tukey post hoc analysis in QPCR, respectively. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of 
this article.) 
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Fig. 5. Sequence variants identiﬁed from transcriptome data. (A) An overview of se- 
quence variants identiﬁed from transcriptome NGS. (B) Single nucleotide variants in 
TP53 and GSTP1 detected in NPC and NP cell lines. Height of sequence logos represents 
the frequency of nucleotides detected at each position. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 note, we discovered a novel TP53 mutation at Chr17:7,579,335T > G
in NP460, HK1, and C666 cell lines. Differences in polymorphism of
GSTP1 (Chr11:67,352,689A > G) across NP460, HK1, and C666-1 were
also found from the NGS data ( Fig. 5 B). 
Sequence variation in the UTR may affect the binding of its regu-
latory miRNA and inﬂuence the level of mRNA expression [ 50 ]. We
sought to analyze the UTR variant that disrupts the miRNA bind-
ing and affects mRNA expression in cell lines. The 712 UTRs from
the reference sequence were predicted to be miRNA binding sites.
Of these miRNA binding sequences, 452 miRNA binding sites were
disrupted by the variation and 184 target sites were predicted to be
enhanced ( Supplement 6 ). We further examined the disrupted / en-
hanced miRNA-binding pairs by referring to the expression of their
corresponding mRNAs and miRNAs. Compared to NP460, almost 100%
of the genes with enhanced variants at the UTR in HK1 and C666 re-
sponded to the changes of the paired miRNAs, while only 41% and
50% of the genes with disrupted variants at the UTR in HK1 and C666
did so. Three examples of the genes with and without disrupted /
enhanced variants are illustrated in Supplemental Fig. 2 . 
From the small library NGS data, we have analyzed human and
EBV-encoded isomiRs based on miRBase and these are listed in
Supplements 7 , 8 and 9 , respectively. Supplement 9 shows the se-
lected top three EBV-encoded isomiRs from C666 and X666 with sub-
stantial expression of isomiRs discovered in RNASeq. The most abun-
dant sequences in 18 C666 and 19 X666 EBV miRNAs are not the ref-
erence ones. Four miRNAs differed from their most abundant isomiRs
in C666 and X666. No reference reads of BART-19–5p were detected
in X666, while only one read detected in C666, mature reference se-
quence was out of top three of all detected sequences in mir-BART18-
3p in both C666 and X666 ( Supplement 9 ). Mature BHRF-1-1-5p wasdetected in both C666 and X666, while BHRF1-2-3p and BHFR1-2-
5p were detected in X666 only ( Table 1a ). Four novel EBV-encoded
miRNAs have been reported by Chen et al. [ 26 ] from clinical samples,
which are not included in the miRBase and further reports are lack-
ing. We have detected three (BART16-3p, BART22-5p, BART12-5p) in
both C666 and X666 samples; the mature sequences as described by
Chen et al. [ 26 ], are the most abundant in BART16-3p and BART22-5p
( Table 1b ). 
3.5. Integrated analysis of transcriptome from model system and 
clinical specimen 
In order to evaluate the importance of different NPC model sys-
tems for translational application, integrated analysis to compare
transcriptomes from cell line systems and clinical specimens was car-
ried out. Meta-analysis of the mRNA gene expression used MetaDE
algorithms [ 45 ] to compare our transcriptome expression against the
microarray datasets from biopsies available from GEO. We combined
the dataset from GSE12452 [ 18 ] and GSE13597 [ 51 ], according to
their stages ( Fig. 6 A). The dataset from GSE34573 - GPL570 [ 52 ] has
no stage information available and we combined the dataset with the
transcriptome according to normal and cancer groups ( Fig. 6 B). C666
and X666, which were alike in origin, are on the same cluster as their
transcript expression patterns are similar. The sample from the C666
microarray GSE34573 (C666.1) and NGS in this study are clustered
close together, validating both studies ( Fig. 6 B). We integrated the
transcript variants to the DNA SNP array data ( GPL3718 / GPL3720 )
from clinical specimens in GEO [ 52 ]. Five SNPs from the coding re-
gion and 7 from the miRNA-binding UTR region were found to have
SNP information from these public datasets ( Table 2 ). C666 RNA and
DNA have been used in NGS and DNA SNP array as control samples,
respectively. Four SNPs differ in genotype between C666 RNA NGS
and DNA SNP array, while ﬁve are in common. 
4. Discussion 
This study provides a global overview of the NPC transcriptome,
explores different variants, and reveals the miRNA regulation of tran-
script expression by integrated analysis of mRNA and miRNA. We
sequenced the mRNAs and small RNAs from the same early passage
of immortalized NP cell line (NP460), two NPC cell lines (HK1 and
C666), and the NPC xenograft (X666). In consideration of genomic and
epigenetic changes arising from longterm in vitro cultivation [ 53 ], we
chose the earliest passage available for sequencing in order to mini-
mize variation introduced from passaging. HK1 and C666 are two NPC
cell lines with a great difference in terms of phenotype and genetic
context; the results of this study provide further comparative insight
in molecular pathways deregulated in NPC. 
In this study we used RNASeq as a platform of analysis. It has
a better sensitivity and dynamic range over traditional microarrays
and enables identiﬁcation of novel as well as more detailed studies
of biological pathways in NPC. From the biological network analysis,
biological pathways such as extracellular matrix (ECM) organization,
PI3K / AKT signaling, and EGFR signaling are commonly enriched in
HK1 and C666 NPC cell line over the immortalized nasopharyngeal
epithelial cell line NP460 ( Fig. 2 B, Supplemental Fig. 1 ). A number of
studies reported dysregulation of ECM pathways in NPC. Members of
ECM pathway such as MMP19, FBLN2, and LTBP-2 had been studied
as tumor suppressors in NPC [ 26 , 54 –56 ], while down-regulation of
hsa-miR-29c was associated with up-regulation of several ECM pro-
teins such as collagens and ﬁbronectins in NPC tumor tissues [ 57 ]. The
PI3K / AKT pathways are important in NPC development and are reac-
tivated by several factors such as PTEN, EGFR, and LMP1 [ 58 , 59 ]. The
commonly enriched pathways are important in both NPC cell lines
as well as NPC development. However, we observed differences in
enrichment and expression levels between HK1 and C666 cell lines in
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Table 1a 
Top three isomirs of EBV-BHRF miRNA from mature miRbase annotated sequence. 
EBV-miRNA Match type a Read sequence 
C666 
read b,d 
X666 
read b,d 
C666 
rank c,d 
X666 
rank c,d 
mir-BHRF1-1-5p **Mature 5 ′ TAACCTGATCAGCCCCGGAGTT 3 8 1st 1st 
Mature 5 ′ sub AACCTGATCAGCCCCGGAGTT 2 N / A 2nd N / A 
mir-BHRF1-2-3p Mature 3 ′ sub TATCTTTTGCGGCAGAAATTG N / A 2 N / A 1st 
**Mature 3 ′ TATCTTTTGCGGCAGAAATTGA N / A 1 N / A 2nd 
mir-BHRF1-2-5p Mature 5 ′ sub AAATTCTGTTGCAGCAGATAG N / A 1 N / A 1st 
a Mature 3 ′ / 5 ′ : **Mature miRbase annotated sequence; Mature 3 ′ / 5 ′ sub: observed tag is shorter than reference sequence; Mature 3 ′ / 5 ′ super: observed tag is 
longer than the annotated mature sequence; Mature 3 ′ / 5 ′ sub / super variant: observed tag with mismatches to annotated sequence. 
b Number of reads detected in NGS. N / A: no read detected in this sample. Total read counts of EBV miRNA of C666: 1761771; X666: 469388. 
c Rank in N / A: ranking of the read in that sample is out of top3. d No mature sequence nor isomirs of mir-BART15-5p found in C666-1 and X666 NGS read. 
Table 1b 
Top three isomirs of novel EBV-BART miRNA from Chen et al. [ 26 ]. 
EBV-miRNA Match type a Read sequence 
C666 
read b,d 
X666 
read b,d 
C666 
rank c,d 
X666 
rank c,d 
mir-BART16-3p ## Mature 3 ′ ATCACCACCCTCTATCCATAT 41 5 1st N / A 
Mature 3 ′ sub / super AGATCACCACCCTCTATCCATA 40 11 2nd 1st 
Mature 3 ′ sub / super AGATCACCACCCTCTATCCAT 39 7 3rd 3rd 
Mature 3 ′ super AGATCACCACCCTCTATCCATAT 9 8 N / A 2nd 
Mature 3 ′ super GATCACCACCCTCTATCCATAT 11 8 N / A 2nd 
mir-BART22-5p ## Mature 5 ′ TGCTAGACCCTGGAGTTGAACC 121 23 1st 1st 
Mature 5 ′ sub TGCTAGACCCTGGAGTTGAAC 55 13 2nd 2nd 
Mature 5 ′ sub TGCTAGACCCTGGAGTTG 3 N / A 3rd N / A 
Mature 5 ′ super variant TGCTAGACCCTGGAGTTGAACCt 3 1 3rd N / A 
Mature 5 ′ sub TGCTAGACCCTGGAGTT N / A 3 N / A 3rd 
Mature 5 ′ variant TGCTAGACCCTGGAGTTGAACa 1 3 N / A 3rd 
mir-BART12-5p Mature 5 ′ super ACCCGCCCATCACCACCGGACA 50 2 1st 1st 
Mature 5 ′ super variant gACCCGCCCATCACCACCGGA 10 N / A 2nd N / A 
## Mature 5 ′ ACCCGCCCATCACCACCGGAC 7 1 3rd 2nd 
Mature 5 ′ sub ACCCGCCCATCACCACCGGA 7 N / A 3rd N / A 
Mature 5 ′ super variant ACCCGCCCATCACCACCGGACt 5 1 N / A 2nd 
a Mature 3 ′ / 5 ′ : ## Mature sequence from Chen et al. [ 26 ]; Mature 3 ′ / 5 ′ sub: observed tag is shorter than reference sequence; Mature 3 ′ / 5 ′ super: observed tag 
is longer than the annotated mature sequence; Mature 3 ′ / 5 ′ sub / super variant: observed tag with mismatches to annonated sequence. 
b Number of reads detected in NGS. N / A: no read detected in this sample. Total read counts of EBV miRNA of C666: 1761771; X666: 469388. 
c Rank in N / A: ranking of the read in that sample is out of top3. d No mature sequence nor isomirs of mir-BART15–5p found in C666–1 and X666 NGS read. 
Table 2 
Common SNPs detected in NGS and GPL3718 / GPL3720 SNP array. 
Transcriptome NGS result GPL3718 / GPL3720 SNP array result 
VarFreq: ratio B / A C666 NPC biopsies (15) Control blood (5) 
Gene Function dbSNP135 
NP460 
VarFreq HK1 VarFreq C666 VarFreq AA AB BB AA AB BB 
CCDC99 Exonic rs3797713 1 0.6034 1 AA 7 6 0 2 3 0 
CEP55 Exonic rs2293277 0.4123 1 0.4487 AB 7 7 1 2 3 0 
PIGC Exonic rs1063412 1 0.5946 1 AB 0 13 1 0 2 1 
GNL3 Exonic rs2289247 0.4375 1 1 AB 11 4 0 2 2 0 
PPA2 Exonic rs13787 0.4058 1 0.3667 AB 6 4 1 0 1 3 
PDLIM5 UTR3 rs13141591 1 1 ND BB 0 0 17 0 0 5 
SQSTM1 UTR3 rs1065154 ND ND 0.6486 AB 3 7 3 3 0 1 
DUSP7 UTR3 rs3821841 0.4731 1 ND AB 4 7 0 5 0 0 
DLX4 UTR3 rs1058564 ND ND 0.6538 AB 10 4 0 3 2 0 
RAB31 UTR3 rs557706 1 0.4528 ND ND 2 8 1 1 0 4 
CERS2 UTR3 rs267739 1 1 1 AB 13 1 0 5 0 0 
CANT1 UTR5 rs3744171 ND ND 0.5 AB 6 5 1 4 1 0 
ND: SNP not detected. 
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Whe same pathway, such as the difference in the number of genes en- 
iched and expressed in the EGFR pathway ( Supplement 4 ). This may 
ccount for the different phenotypes observed between different NPC 
ell types. 
From the miRNA and human UTR sequences, a stringent prediction 
f miRNA targets has been made using three different target predic- 
ion programs. The target pairs were further validated by comparing 
he expression value of miRNA and target pairs, which can serve as 
eferences for further studies on miRNA and its target ( Supplement 3 ). 
e have further validated the expression level of miRNA-regulated biological networks enriched in EGFR, Erb, and Wnt signaling ( Fig. 
3 ). Both hsa-mir-141–5p and hsa-mir-200c-3p are up-regulated in all 
NPC cell lines and belong to the miR-200 family, which controls the 
epithelial-to-mesenchymal transition (EMT) process and regulates 
EGFR activity in bladder cancer [ 60 ]. Hsa-mir-141 is up-regulated 
in NPC biopsies and targets UBAP1, BRD3, and PTEN in the 5-8F NPC 
cell line [ 20 ]. C666 / X666 are the only samples carrying EBV in this 
study and encoding EBV-BART miRNA as described in previous stud- 
ies [ 26 , 61 ]. The MET receptor tyrosine kinase and FAT1 protocadherin 
related to the Wnt signaling pathway [ 62 , 63 ] are the predicted targets 
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Fig. 6. Meta-analysis of NGS data with clinical data from public database. (A) Meta-analysis on GSE12452 , GSE13597 and NGS data; (B)meta-analysis on GSE34573 and NGS data; 
Dotted line: threshold for cluster analysis; circled number: cluster number according to threshold. Both dendrograms in (A) and (B) were generated by MetaDE using complete 
linkage method. (C) Common SNPs detected in NGS and GPL3718 / GPL3720 SNP array. ND: SNP not detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 of ebv-mir-BART2-5p and ebv-mir-BART11-5p, respectively. EGR1, a
transcription factor predicted as a target of ebv-mir-BART17-5p, reg-
ulates transcription of multiple genes such as EGFR, IL1A, and the ErbB
ligand AREG [ 64 , 65 ]. Lowered expression of EGFR was also observed
in C666 compared with NP460 and HK1 cell lines, consistent with the
previous ﬁnding on the EGFR inhibitor trial in vitro [ 66 ]. Dickkopf-Like
protein 1 (DKK1) is a secreted protein that regulates Wnt signaling,
which binds to the frizzled receptor and LRP5 / 6, blocks interaction
with Wnt1 and degrades beta-catenin [ 67 ]. DKK1 is over-expressed
in a number of cancers such as lung, esophageal, and hepatoblastoma
[ 68 ], while this over-expression declines, when prostate cancer de-
velops from primary tumor to metastasis [ 69 ]. The over-expression
of DKK1 in well-differentiated HK1 and down-regulation in the un-
differentiated C666 may imply a similar model for DKK1 during NPC
progression. 
The MHC class II transactivator (CIITA) is regarded as the “master
control factor” of MHC class II (MHCII) genes including HLA class II
genes such as HLA-DQ, -DR and -DP molecules [ 70 ]. MHCII molecules
are an important class of molecules that control and regulate adap-
tive immune responses, which are expressed at high levels in the
majority of NPC tumors, which are EBV positive [ 71 ]. No transcript of
CIITA has been detected in NP460, whilst there is a signiﬁcant, but low
expression in HK1, and its highest expression is in C666 / X666 ( Fig.
4 B). This suggested that CIITA expression has been initiated, even at
a low level, in the differentiated NPC cell stage. Detection of CIITA in
EBV-positive clinical samples [ 71 ] also suggests that CIITA expression
is related to EBV infection. TNFRSF9 / CD137 (Tumor necrosis factorreceptor superfamily, member 9) is a receptor protein that is essen-
tial for M (microfold) cell maturation in nasopharyngeal associated
lymphoid cells [ 72 ]. M cells are specialized for transepithelial trans-
port of foreign antigens and microorganisms to lymphoid tissue, and
most of the studies are limited to the intestinal cells only [ 73 ]. The
up-regulation of TNFRSF9 in C666 may relate to the immune response
against foreign antigens such as EBV. IL18 is a pro-inﬂammatory cy-
tokine that is a major inducer of IFN-gamma, which may serve as
a protective cytokine against cancer; however, blocking of IL18 in
the melanoma model suppresses tumor burden and metastasis [ 74 ].
From our RNASeq and QPCR results, lower transcript expression of
IL18 in HK1 and C666 compared to NP460 has been observed, How-
ever, IL18 protein has been reported to be expressed in NPC biopsies,
but not normal NP biopsies and mRNA expression has been detected
in HK1 [ 75 ]. In the previous literature, only mRNA expression of HK1
and CNE2 has been reported and no comparison is reported for HK1
against the NP cell line NP460 as well as C666. The lower mRNA ex-
pression of IL18 in NPC cells, especially in C666, may suggest the
pro-inﬂammatory function of IL18 lowering immunological defense
against cancer. The mechanism for IL18 being down-regulated in HK1
and C666, but up-regulated in NPC biopsies remains unclear and re-
quires further investigation. Epigenetic change is a common mecha-
nism in gene regulation. The altered epigenetic signature at this gene
in NPC cell lines and biopsies might be one explanation for the dis-
crepancy. Nevertheless, caution must be taken to explain the disparity
observed for IL18 in different NPC model systems. 
Apart from expression analysis, we have analyzed the sequence
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6ariants and their relationship to expression. Besides proteins en- 
oding SNV / INDEL, a large portion of sequence variants are located 
n UTRs of the mRNA transcript whose function still remains un- 
nown ( Fig. 5 A). The analysis of SNV, short INDEL, and UTR sequence 
ay provide a possible opportunity for further mechanistic studies 
 Supplements 5 and 6 ). From the TP53 mutant database [ 76 ], we dis- 
overed a novel TP53 mutation at the HCDII binding domain. From 
he RNASeq data of NP460, HK1, and C666 cell lines ( Fig. 5 B), this 
-to-G variation occurs in the range of 30% to 50% of the total tran- 
cripts ( Supplement 5 ). The mutation causes an amino acid change 
Thr118 > Pro) at the DNA binding domain, reducing transactivation 
ctivity in various promoters (14-3-3- σ, AIP, BAX, GADD45, MDM2, 
OXA, p53R2, WAF1) from 50% to 90% in a TP53 yeast mutant library 
 77 , 78 ]. TP53 is a tumor suppressor protein that highly expressed in 
PC [ 79 ]; several TP53 polymorphisms have been reported in NPC. 
owever, the results are controversial and the function of TP53 in 
PC is still inconclusive [ 80 ]. This novel TP53 variant may suggest a 
ew mechanism for the TP53 pathway in the nasopharyngeal cell and 
PC development. We also identiﬁed a differential variation of GSTP1 
NV in NP and NPC cell lines. All of the transcripts from RNASeq were 
n T-to-C variant (rs1695 / rs947894) form in C666, whilst only wild- 
ype GSTP1 was found in NP460, and around 65% of the variants are 
ound in HK1 ( Fig. 5 B). This polymorphism is reported to lower en- 
yme activity of GSTP1 [ 81 ] and has been reported in NPC and the Han 
hinese population [ 82 ]. Since GSTP1 is an enzyme detoxiﬁcation en- 
yme, as well as the regulator of MAP kinase pathway in cancer [ 83 ], 
aution must be taken when using NP and / or NPC cell line models 
ith different degrees of GSTP1 functional polymorphism. 
IsomiRs are heterogeneous variants of miRNAs in length and se- 
uences, which may affect target selection, miRNA stability, and 
ranslational machinery. Recently, some isomiRs are reported to have 
iological signiﬁcance in plants and animals [ 28 ]. We have listed the 
somiRs from the NGS data for both human and EBV-encoded miR- 
As for future reference ( Supplements 8 and 9 ). Furthermore, we 
nalyzed the EBV-encoded isomiRs from the C666 and X666 samples, 
o compare against a previous report of the EBV miRNAome from 
linical tissues [ 26 ]. Most isomiRs are length variants; some of the 
somiRs are expressed in even higher levels than the reference ma- 
ure sequence ( Supplement 9 ). IsomiRs of EBV-miR-BART19-5p have 
een found highly expressed (top three) in both C666 and X666 sam- 
les, consistent with the genomic variant discovered in C666 from 
 previous report [ 26 ]. Four novel EBV-encoded miRNAs have been 
dentiﬁed from clinical samples in Ref. [ 26 ]. However, they are not in 
he miRBase (release 19) collection and further reports of these miR- 
As were limited. Here we have identiﬁed expression of three out 
f four novel miRNAs and their isomiRs (EBV-miR-BART16-3p, EBV- 
iR-BART22-5p, EBV-miR-BART12-5p) in both C666 / X666 samples 
 Table 1b ). We have detected EBV-miR-BART12-5p isomiRs as the 
ost abundant reads in C666 / X666, which is expressed in unde- 
ectable levels in previous reports, respectively. The function of these 
somiRs in NPC development remains elusive. It has been reported 
hat the isomiRs might functionally cooperate with canonical miRNAs 
o target pathways of functionally related genes [ 84 ]. Only precursors, 
ut no mature reads of EBV-miR-BART22-5p, have been detected from 
he RNASeq results (data not shown), whilst detection of this miRNA 
as been described in C666 in previous reports [ 23 , 26 ]. We also de- 
ected EBV-encoded BHRF mature miRNA in a low number of reads. In 
ontrast to a previous report on detection of BHRF1-1-5p,1-2-3p and 
HRF-1-3 in C666 [ 85 ], mature BHRF-1-1-5p was detected in both 
666 and X666, while BHRF1-2-3p and BHFR1-2-5p were detected 
n X666 only ( Table 1a ), and only the precursor of BHRF1-3 has been 
etected (data not shown). 
To explore the translational relevance of the transcriptome in 
odel systems, we have integrated our NGS data from model sys- 
ems to the expression / SNP array data from clinical specimens. Fig. 
 a and b shows the clustering result of meta-analysis of NGS data to the public data according to the stage information and cancer / non- 
cancer information, respectively. The NPC cell lines were clustered 
with different groups of clinical samples, suggesting that the two NPC 
cell lines can be used as models of different types of NPC. C666 and 
X666 were in the same cluster as they are from the same cell ori- 
gin. To our surprise, the expression pattern of NP460 does not cluster 
with the normal control samples for all three microarray studies from 
biopsies. Furthermore, we have analyzed the known SNV in the SNP 
database with the DNA SNP array result ( Table 2 ). Due to the few 
SNPs available from array data in the literature, the number of SNPs 
consistent with the NGS data is limited; C666 has not been analyzed 
speciﬁcally as a control. Four SNPs have a different genotype between 
C666 RNASeq and DNA SNP array, while ﬁve are common. The dif- 
ference may imply technical difference and / or post-transcriptional 
editing in RNA. Post-transcriptional editing of RNA in cancer has been 
demonstrated in hepatocellular carcinoma (HCC) [ 86 ], but examples 
in NPC have yet to be discovered. rs557706 (3 ′ UTR of RAB31) has the 
same genotype (BB) in NP460 and 4 / 5 of the controls, and a similar 
genotype (AB) in HK1 8 / 15 of the NPC biopsies, suggesting that NP460 
and HK1 can be used as the model system for mechanistic studies in 
this SNP. However, the numbers of publicly available high-throughput 
data sets are limited in NPC and are conducted in a different platform 
without proper internal control such as using C666 as a calibrating 
sample, increasing difﬁculties in analyzing data across studies. More 
high-throughput studies on clinical samples with detailed informa- 
tion and proper controls would be needed in the future. 
Here we report a comprehensive characterization of mRNA and 
miRNA transcriptome in NPC cell lines and xenograft from expression 
level and sequence variation, miRNA / mRNA regulation on biological 
network, integrated analysis on expression-to-sequence characteris- 
tics and model system-to-clinical specimen. This will provide a valu- 
able reference for future studies in transcript variation and regulation 
of NPC in in vitro model cell lines and xenograft and will potentially 
be useful for mechanistic and preclinical studies. 
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